* Sales -1%, adj. EBITA -8% vs. FactSet consensus * Earnings miss driven by Sweden and Norway * Expe...
Redeye comments on Vitec's Q3 report, which came in largely in line with our expectations, with marg...
Duni reported organic sales of 1.7% y/y in Q3, better than SEBe -2% (+3.
* New SEK 39m order from its newest NATO customer * Mobile satellite terminals, deliveries in Q4'26-...
Redeye comments on Addnode's strong Q3 report, where EBITA beat our forecast by 23%, driven by a sub...
Xvivo delivered a solid Q3 report, beating our estimates and consensus on both sales and EBIT.
Redeye provides its initial take on MedCap’s Q3 2026 report, which came in broadly in line with our ...
We believe that Q3 was positive for Bactiguard. Notably, there was strong q/q growth for BD revenue ...
Net sales and adjusted EBITA were around 2-3% above market consensus (LSEG) in Q3.
Ahead of SSH’s Q3 report on 28 October, we expect net sales of EUR 5.
* Transaction activity improving while AUM remains subdued * EBIT estimates cut for 2026-28e * Cost ...
Fiskars' Q3 results were fairly solid, with profitable growth accelerating q/q in both business area...
Vitrolife’s Q3 sales came in 4% above consensus at SEK884m, driven by 21% organic growth in Technolo...
Enea's Q3 net sales of SEK202m were 10% below our estimate, and currency-adjusted growth was -6% aga...
We raise our Base Case to SEK46 (44) after a clear Q3 beat, with adjusted EBITA 16% above our foreca...
* Minor deviations amplified by break-even earnings * Slower TPV growth drives earnings downgrades *...
* Signs of stabilisation in the market... * ...and we are positive on the 2027 story * Trading below...
* Unforeseen organic decline in the UK still above the market * We cut '27e EBITA by 2%, EPS by 6% o...
Nelly delivered a better-than-feared Q3, although the recovery was driven by higher volumes rather t...
* Q3'26: Margin held up but volumes did not * We cut '26e-'27e EBITA by 7-2%, mainly on North Europe...